Tata Elxsi Q1: revenue +14.5% YoY beats guidance pace, PAT ₹171 Cr up 18%, margins firm YoY
PAT +18.17% YoY · revenue +14.46% · margins expanding
₹1,021.11 Cr
+14.46% YoY
₹170.6 Cr
+18.17% YoY
16.06%
+0.5pp YoY
₹27.38
Tata Elxsi opened FY27 with a clean reacceleration on a standalone basis (its only reporting basis — no subsidiaries). Revenue from operations rose to ₹1,021.1 Cr, up 14.5% YoY from ₹892.1 Cr and up 2.8% sequentially, comfortably ahead of the high-single-digit full-year growth pace management guided to on the Q4 concall. Net profit came in at ₹170.6 Cr, up 18.2% YoY from ₹144.4 Cr, with EPS at ₹27.38 versus ₹23.18 a year ago. There were no exceptional items either this quarter or in the year-ago quarter, so the growth is fully underlying — the ₹95.7 Cr New Labour Codes charge that dented FY26 sat in Q3, not in these comparatives.
Q1 FY-2027 vs prior quarters
The margin picture is a YoY-versus-QoQ split. Against last year, both net margin (16.7% vs 15.5%) and operating/EBITDA margin (~21.2% vs 20.9%) expanded modestly. Sequentially, however, profit fell 22.6% off an unusually strong Q4 (₹220.4 Cr PAT, 21.1% NPM, 24.6% OPM) that carried richer other income (₹50.6 Cr vs ₹41.5 Cr) and peak margins — so Q1 reads as a seasonally soft, normalised quarter rather than a deterioration. By segment, Software development & services delivered ₹992.3 Cr (+13.7% YoY) and the small System integration & support business grew ₹28.8 Cr (+46.8% YoY), swinging from a ₹2.6 Cr year-ago segment loss to a ₹3.1 Cr profit.
The stock went into the print at ₹3,697.3, down 9% over the past month of trading.
For context: revenue is at a 6-quarter high.
What the summary numbers don't show
Audited, unmodified auditor opinion — standalone only (no subsidiary/associate/JV); first result under new CFO Nalin Rana.
Management has tempered its full-year FY27 outlook, now guiding for high single-digit revenue growth, a revision from previous double-digit aspirations, citing geopolitical uncertainty. They are hopeful for a recovery in the Healthcare vertical from Q1 after a sharp decline due to deal delays. The company will continue
— This quarter: beat
No specific Q1 FY27 street consensus surfaced in our search (previews were qualitative, flagging a seasonally weak quarter and geopolitical headwinds), so a beat/miss call against consensus is unavailable. Against management's own framing, the topline is running ahead of the tempered high-single-digit FY27 guide, but the stated ~27% exit-PBT-margin target for Q4 FY27 remains a distance away — PBT margin this quarter was ~22.8% of revenue. Management had also flagged a hoped-for Healthcare recovery from Q1 after Q4's sharp deal-delay-driven decline; the vertical split isn't in this filing and is the key item for the 7pm concall. The quarter's corporate backdrop was light on financial impact: a ₹1.58 Cr tax demand notice (immaterial), the Sky/NEURON autonomous-networks partnership, and the FY26 ₹75 dividend/AGM cycle; this is also the first print under new CFO Nalin Rana.
What to watch
W1
Healthcare vertical recovery: management guided a Q1 rebound after Q4's ~13% CC QoQ decline — verify in the concall vertical split, absent from this filing.
W2
PBT-margin trajectory toward the ~27% Q4 FY27 exit target (currently ~22.8% of revenue) — the main margin checkpoint for the year.
W3
Full-year revenue vs the high-single-digit guide: Q1 ran at +14.5% YoY — watch whether it sustains given the cited geopolitical headwinds.
Clean digital PDF, clear headers, all arithmetic ties (1021.11+41.46=1062.57 income; 1062.57-830.11=232.46 PBT; 232.46-61.86=170.60 PAT). No exceptional item this quarter; the ₹95.69 Cr New Labour Codes charge sat in Q3/FY26 full-year only, so Q1-on-Q1 comparison is clean (adjusted=raw). Standalone only — no subsidiary/associate/JV. Unmodified audit opinion.
Guidance held but margins tumbled—FY27 hinges on healthcare and wage-hike absorption
The company posted ₹1,021 Cr revenue and ₹171 Cr profit, maintaining FY27 high-single-digit growth guidance at a constant-currency 6.5%—the floor, not a stretch. But EBITDA margin cratered 330 basis points quarter-on-quarter to 21.2%, and healthcare, which management pegged as essential to FY27, flat-lined. With wage hikes looming in Q2, the path to recovery narrows.
₹1,021 Cr
+6.5% CC (constant-currency) — guidance floor
+18.2% YoY
₹170.6 Cr, masking -22.6% QoQ decline
21.2%
-330 bps QoQ — cycle low
+6.5%
Forex added ~800 bps to nominal +14.5%
On the headline, TATA ELXSI looks robust—profit up 18%, revenue past ₹1,000 Cr. But the quarter is messier than the numbers suggest. Strip away forex (which inflated nominal growth to 14.5% from an underlying 6.5%), and you have a company grinding along at the bottom of its FY27 growth aspiration. Dig into the profit, and the YoY gain evaporates quarter-on-quarter: PAT fell 22.6% in three months, a sequential cliff the market read immediately as weakness. EBITDA margin contracted 330 basis points, the steepest single-quarter drop of the year, driven by 370 basis points of headwinds—some temporary (one-timers), some structural (AI investments, onsite ramp). And the healthcare segment, flagged by management as key to FY27's growth story, never showed up: it was flat QoQ, a silent miss that undercuts the guidance.
Where the margin pressure came from
Management disclosed a clean breakdown of the 330 basis point QoQ margin compression: 150 basis points of one-timers (transition costs, retention bonuses, upfronted annual accruals that should normalize next 1–2 quarters) and 220 basis points of strategic investments (onsite labour ramp, third-party subcontractors to offset visa constraints, and AI infrastructure for platforms like Neuron and ViTel). This transparency is valuable, but the near-term path is grim: Q2 will see the full brunt of company-wide wage hikes hitting (magnitude unspecified), only partially offset by the one-timers rolling off. Management expects sequential margin improvement H2 as wage hikes embed into the revenue base, but the trough is coming.
One-time costs (transition, retention, upfronting)
150 bpsFade over next 1–2 quarters (Q2–Q3)
Strategic investments (onsite, subcontractors, AI platforms)
220 bpsStickier; improve over time as deals ramp and platforms monetize
Total margin headwind
370 bpsQ2 worse (wage hikes added), H2 recovery conditional on revenue growth
Claims vs. what holds up
FY27 high-single-digit growth aspiration maintained
… but Q1 landed at the floor (6.5% CC), not a stretch. Healthcare recovery needed to hit the midpoint
Media & communication delivered strong 11.5% YoY growth
Transport held at 6.7% YoY despite Europe softness and OEM hesitation
Healthcare expected to fire up in FY27 as key growth driver
… but Q1 was flat QoQ; deal awards stalled. No inflection yet
Margin investments are temporary; one-timers will roll off cleanly
… but strategic drag (220 bps) is stickier, and Q2 wage hike timing/quantum TBD
What changed this quarter
Media & communication surprised to the upside. Growth of 11.5% YoY marks a turnaround from prior underperformance. M&A consolidation in telecom and media is feeding deal ramp-ups, and the company is benefiting from customer integrations. This is the one segment firing on plan. Healthcare disappointed. The segment was positioned as the growth engine for FY27 (contingent on 'health' per prior guidance). Instead, Q1 delivered -0.3% QoQ, a silent miss. Management blamed delayed deal awards from key customers and deferred the recovery to 'later in FY27.' This hedge erodes confidence in the annual target. Margin guide was not restated. Management said Q2 would be pressured by company-wide wage hikes, partially offset by one-timer roll-off. But no explicit margin floor or ramp trajectory was re-committed. This vacuum suggests internal uncertainty on hike magnitude or the pace of recovery. AI capex acceleration entered the narrative. The company disclosed 220 basis points of margin drag from AI infrastructure, specialized talent hiring, and platform upfronting (Neuron for network ops, ViTel for medtech). These are real investments, but monetization is a multi-quarter bet.
The bull-bear ledger
Revenue milestone crossed (₹1,000+ Cr quarterly). Structural growth trajectory intact
Media M&A tailwinds showing up in +11.5% YoY growth; platform traction (Neuron, ViTel) gaining customer credibility
FY27 high-single-digit guidance maintained despite margin headwinds; management tone confident on long-term
OEM concentration rising (now 78% of auto) but deepening tier-1 relationships defensible in SDV era
YoY profit growth 18.2% masked -22.6% QoQ decline; sequential weakness contradicts headline strength
EBITDA margin 21.2%, cycle low (-330 bps QoQ). Q2 will see wage-hike cliff before any one-timer relief
Healthcare flat; management's FY27 contingency is now manifesting. No near-term inflection visible
Wage hike quantum deferred to Q2 disclosure. Lack of specificity suggests internal sensitivity or debate
One customer (Chapter 11) added to credit-risk roster. Diversification still in progress
Visa constraints forcing subcontractor spike (onshore ratio +90 bps in one quarter). Margin drag extends beyond one-timers
Risks, ranked by how much they should concern a holder
Margin sustainability post-Q2
HighEBITDA margin at 21.2% is a cycle low. Q2 wage hikes will deepen the trough before one-timers (150 bps) fade. If strategic investments (220 bps) don't monetize on schedule or hikes exceed embedded assumptions, the margin floor sinks further.
Healthcare segment recovery delayed
HighFlat Q1 was a miss. Management flagged healthcare as 'contingent' to hitting high-single-digit annual growth. If deal awards remain delayed, the company misses guidance without transport and media overperforming to compensate.
Wage hike quantum and timing opacity
MediumManagement declined to quantify the hike, deferring to Q2 results. This suggests internal debate or sensitivity. Q2 margin impact is now a wild card, and guidance credibility is at stake.
Visa constraints and subcontractor dependency
MediumOnshore ratio spiked 90 basis points in one quarter due to H-1B scarcity. Subcontractor costs are cited as 'tactical,' but the structural visa shortage persists. If restrictions tighten, the company normalizes at a higher onshore-cost baseline.
Customer concentration and credit events
MediumChapter 11 bankruptcy materialized in Q1, leading to provisions. OEM is now 78% of auto revenue. Media/telecom consolidation creates re-evaluation risk. Diversification is under way but not yet defensive.
Europe automotive demand and macro headwinds
Low-MediumEurope contributes ~40% of transport revenue; German OEM slowdown cited as 'wait and watch.' Middle East conflict cited but impact unquantified. US/APAC recovery has offset so far, but European deterioration could drag the headline.
How the street is positioned
The market's verdict was swift and skeptical. The stock fell 4.78% on day 1 post-announcement and by day 5 the loss widened to -6.37%—a rejection that never faded. Delivery on results was solid (45.7%), but institutional appetite retreated. FII ownership ticked up 252 basis points to 11.09% (buying the dip or rebalancing into weakness is unclear), while DII trimmed 90 basis points to 11.39%. Promoters held steady at 43.90%. The stock now trades at ₹3,672.9, down 38.27% from its all-time high of ₹5,950, trading below its 50-day average (₹3,911.49) and well below the 200-day (₹4,656.11). RSI at 41.2 suggests oversold conditions, but the stock has found no natural bid.
This divergence—FII adding while DII retreats and price keeps falling—hints at disagreement on whether this quarter is an entry point or further deterioration. The fundamental read supports caution: guidance maintained, not raised; healthcare disappointed; margins are at cycle lows. But the drawdown from ATH is severe enough that downside risk per rupee may be limited. The market is pricing in multiple quarters of margin pressure and healthcare delays before recovery accelerates.
The debate
What to watch next
1 · Q2 margin trajectory after wage hikes
Management guided to 'combination of wage hike headwinds and one-timer roll-off' in Q2. Net impact is unknown. If EBITDA margin stays above 20%, the narrative holds (temporary pain). If it slips below 20%, the floor has shifted lower, and FY27 operating leverage is at risk.
2 · Healthcare segment inflection
Flat Q1 was a miss. Management expects deal closures later in FY27. By Q2 end, early signals of pipeline conversion (new announcements or ramp-ups) would validate 'recovery on track.' Silence suggests continued delays.
3 · Platform monetization evidence
Neuron (network ops delivering '30–70% efficiencies') and ViTel (medtech AI) are 220 bps of Q1 margin drag. Any announcement of new customer wins or scale-out would show investments are working. Current silence leaves the thesis on faith.
4 · Margin ramp H2 FY27
Management expects sequential improvement from Q3 as wage hikes embed and one-timers fully fade. If Q3 EBITDA margin is still sub-21%, the entire FY27 narrative (strategic investments + H2 recovery) is suspect.
TATA ELXSI is executing a strategic bet—investing in AI, platforms, onsite labour—under the assumption these translate to pricing power and deal velocity by FY27 end. The company maintained guidance, but Q1 shows the cost: margins at a cycle low, healthcare flat, wage hikes incoming. This is steady execution in transition, not deterioration or step-change.
For holders, the single number to track from here is organic EBITDA margin (ex. one-timers and investments)—what the underlying run-rate looks like once the transition absorbs. If that's sustainably 21%+, the stock's 38% drawdown is an entry. If it's lower, the multiple contraction has further to run. Constant-currency growth (6.5%) is solid. The margin path is the riddle.
Growth at guidance floor, margins at cycle lows from strategic investments
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met FY27 growth aspiration (6.5% CC is high-single-digit floor). Transparent on margin drivers: 150 bps one-timers (should fade), 220 bps strategic investments. Wage hike timing disclosed, but quantum deferred to Q2 results.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Tata Elxsi held FY27 high-single-digit growth guidance with Q1 constant-currency growth of 6.5%, at the floor. Revenue milestone reached, but net profit YoY growth (18.2%) masked by -22.6% QoQ decline and EBITDA margin compressed 330 bps to 21.2% from strategic investments (AI, onsite ramp, talent) and one-timers (transition, Chapter 11 provision). Healthcare segment flat contrary to growth aspiration. Near-term margin pressure (Q2 wage hikes) offsets long-term platform investments and M&A tailwinds.
₹1021.1 Cr
Revenue · +14.5% YoY₹170.6 Cr
Reported PAT · +18.2% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
High-single-digit growth for FY27
METConstant currency 6.5% YoY in Q1; nominal 14.5% inflated by forex
Media & communication delivered robust growth
MET11.5% YoY CC; 4.7% QoQ natural currency—strong vs peers but from low base
Transportation growth led by OEM
MET6.7% YoY CC; OEM now 78% of auto revenue; US/APAC offset Europe softness
Healthcare expected to fire up in FY27
OVERSTATED-0.3% QoQ CC in Q1; deal awards delayed. No momentum yet.
Margin investments are temporary, one-timers will roll off
Partial370 bps of headwinds: 150 bps one-timers (transition, retention, upfronting), 220 bps strategic (onsite, subcontractors, AI). Real run-rate pressure evident.
Earnings quality
What changed since the last call
Media & comm ramped; transport steady
UpgradeMedia +11.5% YoY vs prior quarter underperformance; M&A tailwinds realized. Transport +6.7% YoY but Europe softness offset by US/APAC recovery.
Healthcare stalled
DowngradeExpected growth; delivered -0.3% QoQ. Delayed deal awards from key customers. Contingency flagged in prior guidance now manifesting.
Margin guide not restated
WithdrawnPrior call indicated margin pressure in Q2 due to wage hikes (now confirmed, but quantum TBD). No 21%+ EBIT margin guidance stated; 19% floor implied for subsequent quarters, but with caveats.
AI capex acceleration
NewInvestments in AI infrastructure, specialized talent, and platforms (Neuron, ViTel) accelerated; 220 bps of margin drag in Q1, expected to improve as platforms monetize.
The Q&A
Analysts pressed hard on margin sustainability, onsite/offshore ratios, wage hike quantum, and contractor dependency. Management held firm on FY27 growth aspiration, defended margin compression as temporary/strategic, and clarified onsite ramp is tactical not structural. Some evasion on wage hike number (deferred to Q2), but otherwise direct and data-backed.
Vertical outlooks & margin trajectory — Bhavik Mehta, JP Morgan
AnsweredTransport 6.7% YoY, media 11.5% YoY. Europe soft but US/APAC strong. Margin headwinds: 150 bps one-timers (fade in 1–2 Q), 220 bps investments (stickier, improve over time as deals ramp).
Auto OEM & adjacencies disclosure — Vimal Jamnadas Gohil, Alchemy Capital
PartialOEM 78% of auto revenue. Adjacencies quantification by end of FY27. No specifics given on current mix.
Transport pipeline & hybrid platforms — Ravi Menon, Axis Capital
AnsweredStrong SDV pipeline in US/APAC. Utilization 75%, hiring freshers moderated (100–150 added Q1). Sales headcount added in US/Europe; spending on industry events for brand visibility.
FY27 growth guidance maintenance — Moez Chandani, Ambit Capital
AnsweredGuidance unchanged; healthcare growth needed to hit target. AI adoption cautious/measured; no client deflation expected. Domain complexity, regulatory rigor keep pricing power intact.
Investment types & deal margin profile — Amit Chandra, HDFC Securities
AnsweredMix of talent, AI infrastructure, cloud, tools. Large deals have 3–5 year lifecycle with front-loaded transition bubble costs. Platform investments separate (not deal-specific).
AI deflation protection; platform traction — Karthik, RK Investments
AnsweredCoding is 1 part of SDLC; product planning/architecture/regulatory align larger. Customers prioritize quality/time over cost. Platform traction fantastic; adoption calibrated/long-term, not transactional.
Onsite investment: structural or tactical? — Sulabh Govila, Morgan Stanley
AnsweredTactical for current consolidation deals. Target remains 75/25 (offshore/onsite). Partial revenue uplift visible in Q1 US/media; full benefit Q2+.
Transport geography split; margin floor — Karan Uppal, PhillipCapital
PartialEurope ~40%, US ~25–30%, APAC remainder. Q2 wage hikes offset by one-timer removal; post Q2, sequential ramp as revenue grows and wage hike baked in.
Contractor demand trend; wage hike quantum; AI R&D shift — Abhishek Shindadkar, InCred Capital
PartialVisa-driven (H-1B scarcity), not customer demand. Wage hike quantum deferred to Q2 results. AI shift is budget reallocation, not permanent R&D cuts.
M&A tailwinds; customer concentration; visa cost pass-through — Rishi Mody, Mody Advisory
AnsweredBoth roles, but company not being re-evaluated (demonstrated superior value). Visa fees absorbed into COLA negotiation; no line-item pass-through to customers.
Attrition; wage hike rationale — Sulabh Govila, Morgan Stanley (follow-up)
AnsweredAttrition 16% overall, but niche AI/domain talent highly competitive. GCCs hiring aggressively. Need to retain key talent ahead of revenue ramp.
Q2 margin trajectory & wage hike offset — Randhir Singh, Randhir HUF
AnsweredQ2 wage hike offset by one-timer removal; net impact TBD based on hike quantum and cost normalization. H2 ramp as hikes fully baked, revenue accelerates.
Guidance
FY27 high-single-digit growth aspiration maintained
MediumContingent on healthcare segment recovery. Q1 delivered 6.5% CC (at lower bound). Media/transport visibility strong for 2–3 quarters; healthcare timing uncertain.
Q2 margin pressure from company-wide wage hikes; offset partially by one-timer cost roll-off
Medium150 bps of one-timers (transition, retention, upfronting) expected to exit next 1–2 Q. 220 bps of investments (onsite, subcontractors, AI) stickier, to improve over time. Wage hike quantum TBD.
Sequential margin ramp H2 FY27 as wage hike costs embedded, revenue growth accelerates
MediumQ2 will be 'combination of two things' (wage hikes + one-timers going away). Post-wage hike baking, ramp up expected toward Q4.
Risks the call surfaced
Segment performance variability
HighHealthcare expected to drive FY27 growth; Q1 delivered -0.3% QoQ. Delayed deal awards from key customers. If healthcare remains flat/negative, high-single-digit FY27 target becomes very aggressive.
Geographic & macro exposure
MediumEurope contributes ~40% of transport (auto) revenue. Germany OEM slowdown noted; 'wait and watch' stance. Deal ramp-ups slowing in Europe. Middle East conflict headwinds cited but not quantified.
Margin sustainability
HighQ1 EBIT margin 21.2% (-330 bps QoQ). Management attributed to 370 bps of headwinds. Q2 wage hikes will further pressure margins. 220 bps of investments (onsite delivery, AI tools, specialized talent) expected to 'improve over time' but quantum and timeline vague.
Customer concentration & credit
MediumOne customer filed Chapter 11 in Q1, leading to higher provisions (reflected in ₹135 Cr other expenses). OEM now 78% of auto revenue, concentrated in large tier-1s. Media/telecom consolidation creates customer concentration risk if acquirer re-evaluates.
Visa & labor cost inflation
MediumUS ramp-ups constrained by visa availability. Company using third-party contractors (~90 bps onshore ratio increase in Q1) as stopgap. Visa fees (including H-1B $100k+ stories) cannot be passed to customers; absorbed internally or hedged via COLA negotiations.
Management
Score 7/10. Transparent on margin drivers (370 bps breakdown), but deferred wage hike quantum to Q2. Candid on healthcare miss, Europe softness, and customer credit event. Some deflection on subcontractor cost quantification (acknowledged 90 bps ratio shift but declined to provide % of revenue). Met high-single-digit FY27 guidance (6.5% CC in Q1, at lower bound). Prior call guidance on margin pressure in Q2 confirmed. Media & communication turnaround delivered (11.5% YoY). But healthcare miss (expected growth, delivered flat) and sequential PAT decline (-22.6% QoQ) against backdrop of investments signal execution risk in near term.
1 · Q2 FY27
Company-wide wage hike implementation; margin impact vs one-timer fade-out
2 · H2 FY27
Margin ramp-up as wage hikes baked in, revenue growth accelerates, onsite costs normalize
3 · FY27 end
Quantified disclosure of adjacency revenue (off-road, farm, aerospace contribution to transport)
Near-term margin pressure (Q2 wage hikes) offsets long-term platform investments and M&A tailwinds.